Lipella Pharmaceuticals Inc Stock Price, News & Analysis

Lipella Pharmaceuticals (Nasdaq: LIPO) is set to present clinical data on LP-20, a novel MRI contrast agent, at the 5th International Consultation on Interstitial Cystitis Japan (ICICJ) in Kyoto, August 21-23, 2024. LP-20 is designed to diagnose interstitial cystitis and detect bladder cancer using advanced MRI technology to identify bladder permeability defects.

The contrast agent, which has completed preclinical and proof-of-concept human trials, is administered via catheter into the bladder. It shows promise as a rapid and cost-effective diagnostic solution for these conditions. LP-20's development was partially funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Lipella Pharmaceuticals (Nasdaq: LIPO) has dosed the first two patients in its Phase 2a clinical trial for LP-310, a novel liposomal-tacrolimus oral rinse targeting Oral Lichen Planus (OLP). OLP is a chronic inflammatory condition affecting about 6 million Americans, with no FDA-approved therapies currently available. The multicenter, dose-ranging study involves adult subjects with symptomatic OLP and is expected to conclude in mid-2025. Lipella anticipates reporting top-line data by the end of 2024. LP-310 aims to address the underlying mechanisms of OLP, potentially offering substantial symptom relief and reduced complication risks. This trial represents a significant step towards developing the first approved drug treatment for OLP, addressing a critical unmet medical need.

Lipella Pharmaceuticals (Nasdaq: LIPO), a clinical-stage biotech company, has announced a $1.28 million registered direct offering of common stock priced at-the-market under Nasdaq rules. The offering includes 2,066,000 shares at $0.62 per share or pre-funded warrants. H.C. Wainwright & Co. is the exclusive placement agent. The offering is expected to close around August 1, 2024, subject to customary conditions. Lipella plans to use the net proceeds for working capital and general corporate purposes. The securities are being offered through a previously filed and effective shelf registration statement on Form S-3.

Lipella Pharmaceuticals (Nasdaq: LIPO) has initiated a Phase 2a clinical trial for LP-310, enrolling the first patients to evaluate its efficacy in treating Oral Lichen Planus (OLP). This chronic inflammatory condition affects over 6 million Americans and currently lacks FDA-approved treatments. The multi-center, dose-ranging study is testing LP-310, a proprietary liposomal-tacrolimus oral rinse formulation derived from Lipella's lead candidate LP-10 for hemorrhagic cystitis.

The trial has commenced across multiple research sites nationwide, from Philadelphia to San Francisco. Lipella expects to conclude the trial by mid-2025, with top-line data anticipated by year-end 2024. LP-310 aims to address the underlying causes of OLP, potentially offering a transformative therapy that could alleviate symptoms and improve patient outcomes while minimizing systemic toxicity.

Lipella Pharmaceuticals (Nasdaq: LIPO) announced the completion of its first Site Initiation Visit (SIV) for the Phase 2a trial of LP-310, targeting Oral Lichen Planus (OLP). The trial, starting in mid-2024, will involve 24 adult subjects across five U.S. sites. LP-310, a proprietary liposomal-tacrolimus oral rinse, will be tested for safety, tolerability, and efficacy at doses of 0.25 mg, 0.5 mg, and 1.0 mg. The study addresses the unmet need for an FDA-approved OLP treatment and is expected to conclude in mid-2025. Lipella's CEO and CMO expressed optimism about providing a potential treatment for the 6 million Americans suffering from OLP.

Lipella Pharmaceuticals (Nasdaq: LIPO) announced the publication of an abstract at the 2024 American Society of Clinical Oncology (ASCO) annual meeting. The abstract, titled “Intravesical Administration of Pembrolizumab for Bladder Tumor- A Potential Strategy to Minimize Drug Toxicity,” presents new preclinical data for LP-50, an intravesical formulation for treating non-muscle invasive bladder cancer (NMIBC).

The preclinical results indicate that LP-50 has the potential to increase efficacy while reducing systemic toxicity. Dr. Michael Chancellor, the Chief Medical Officer of Lipella, provided insights into these promising results. The ASCO annual meeting will take place from May 31 to June 4, 2024, in Chicago, IL, and online.

The American Cancer Society estimates there will be 83,190 new cases of bladder cancer diagnosed in the United States in 2024.

Lipella Pharmaceuticals (NASDAQ: LIPO) announced FDA guidance for its lead product, LP-10, in a Type-C meeting. LP-10, intended for moderate to severe hemorrhagic cystitis, will enter Phase 2b trials in the second half of 2024. The trial will include around 36 patients and will focus on objectives, safety, control group monitoring, dosing, efficacy endpoints, and sample size. Previous Phase 2a studies showed positive results with improved urinary symptoms in 13 patients. This FDA feedback allows Lipella to proceed confidently with their next trial phase, enhancing their value proposition.